BRIEF—EFPIA response to EXPH draft opinion on payment for high-cost novel meds

The European Federation of Pharmaceutical Industries and Associations (EFPIA) believes that the recently published Expert Panel on Effective Ways of Investing in Health (EXPH) draft Opinion on Innovative Payment models for high-cost innovative medicines represents a missed opportunity to improve patient outcomes and support the sustainability of our healthcare systems.

The mission of the Expert Panel on Effective Ways of Investing in Health is to elaborate evidence-based opinions on matters related to healthcare modernisation, responsiveness and sustainability at the request of the European Commission. It’s a mission that EFPIA and its members are committed to supporting.

But, concerns over the quality of the data used in the draft opinion, its lack of focus and failure to examine forward thinking solutions such as outcome-based approaches or the potential of real world evidence (despite being in the Panel’s terms of reference) means the EFPIA is unable to support the conclusions of the draft opinion in its current form.

However, the EFPIA stands ready to work with the panel to address these concerns and identify real solutions that can benefit patients, our healthcare systems and wider society.

You can access the EFPIA response to Draft Opinion on Innovative payment models for high-cost innovative medicines  here.